Friday, October 23, 2026

Back to today

From X

@StableBread

Fajasy on X

Elmet $ELMT won a ~$36M U.S. defense stockpile contract for metal its plants already make, while deliveries under its $2B stockpile contract wait on new supply. On September 30, Elmet announced the award from the Defense Logistics Agency (DLA), which manages the U.S. National Defense Stockpile. It covers TZM (titanium-zirconium-molybdenum alloy) billets, bar stock, and ingots, plus molybdenum and tungsten wire, materials used to make jet engine components. Elmet's $2B stockpile contract, announced September 14, is separate and covers tungsten concentrate, the upgraded ore a mine ships. The $36M is 27.4% of Elmet's $131.5M total backlog at July 3 ($36M / $131.5M), and the release doesn't say when deliveries start or how long the contract runs. On the slide for the $2B contract, Elmet's October 1 deck says Elmet "does not intend to begin delivering material into the National Defense Stockpile until sufficient incremental new supply is available." Elmet's supply agreement with Tungsten West (AIM: TUN) puts concentrate from Hemerdon, its tungsten mine in Devon, England, first in line for Elmet's DLA deliveries until Elmet's Nevada refinery is commissioned (targeted for 1H 2029). Elmet expects >1,000 tonnes a year of Hemerdon concentrate, and the mine targets full production by the end of Q1 2027. In September I treated $1.85B of the $2B ceiling as an upper bound, not orders Elmet has in hand, and the $36M sits outside the $2B entirely. So the stockpile's newest award goes to metal from Elmet's existing U.S. plants, while the $2B contract still waits on a mine in England that isn't at full production yet.

Capital Wars

CoreWeave’s $35 billion to $39 billion 2026 spending plan relies on debt as unsecured yields reach 15%, making its GPU cloud expansion a…

Putting bear cases to rest

Medpace authorized $1 billion of buybacks through 2028 after Q3 revenue rose 8.5% to $716 million; service revenue grew roughly 12% as…

PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

MYR Group q3’26 Earnings Preview

MYR Group’s Q3 2026 preview cites data-center and power transmission demand, with long-term service agreements supporting margin growth and…

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.